Intellia Therapeutics, Inc.

With $376.0M in cash and $80.5M in debt, NTLA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$235.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -56.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $33.1M (2021) to $67.7M (2025), reflecting a 105% increase over the period.

With a beta above 1.5, NTLA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, NTLA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing NTLA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.